Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Mellins ED, Macaubas C, Grom AA.

Nat Rev Rheumatol. 2011 Jun 7;7(7):416-26. doi: 10.1038/nrrheum.2011.68. Review.

2.

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.

Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C, Fallarino F, De Somer L, Tousseyn T, Quartier P, Wouters C, Matthys P.

Rheumatology (Oxford). 2015 Aug;54(8):1507-17. doi: 10.1093/rheumatology/keu524. Epub 2015 Mar 12.

PMID:
25767156
3.

IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.

Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, Proost P, Fallarino F, Wouters CH, Matthys P.

PLoS One. 2016 Feb 25;11(2):e0150075. doi: 10.1371/journal.pone.0150075. eCollection 2016.

4.

Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Macaubas C, Nguyen KD, Peck A, Buckingham J, Deshpande C, Wong E, Alexander HC, Chang SY, Begovich A, Sun Y, Park JL, Pan KH, Lin R, Lih CJ, Augustine EM, Phillips C, Hadjinicolaou AV, Lee T, Mellins ED.

Clin Immunol. 2012 Mar;142(3):362-72. doi: 10.1016/j.clim.2011.12.008. Epub 2011 Dec 28.

5.

Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis.

Avau A, Put K, Wouters CH, Matthys P.

Cytokine Growth Factor Rev. 2015 Feb;26(1):35-45. doi: 10.1016/j.cytogfr.2014.05.005. Epub 2014 May 24. Review.

PMID:
24948570
6.

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.

Woerner A, von Scheven-Gête A, Cimaz R, Hofer M.

Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257. Epub 2015 Apr 4. Review.

PMID:
25843554
7.

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

Sikora KA, Grom AA.

Curr Opin Pediatr. 2011 Dec;23(6):640-6. doi: 10.1097/MOP.0b013e32834cba24. Review.

8.

Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.

Bruck N, Schnabel A, Hedrich CM.

Clin Immunol. 2015 Jul;159(1):72-83. doi: 10.1016/j.clim.2015.04.018. Epub 2015 May 6. Review.

PMID:
25956529
9.

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.

Behrens EM, Beukelman T, Paessler M, Cron RQ.

J Rheumatol. 2007 May;34(5):1133-8. Epub 2007 Mar 1.

PMID:
17343315
10.

Macrophage activation syndrome and cytokine-directed therapies.

Schulert GS, Grom AA.

Best Pract Res Clin Rheumatol. 2014 Apr;28(2):277-92. doi: 10.1016/j.berh.2014.03.002. Review.

11.

Systemic JIA: new developments in the understanding of the pathophysiology and therapy.

Vastert SJ, Kuis W, Grom AA.

Best Pract Res Clin Rheumatol. 2009 Oct;23(5):655-64. doi: 10.1016/j.berh.2009.08.003. Review.

12.

Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.

Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G.

J Pediatr. 2013 Jun;162(6):1245-51. doi: 10.1016/j.jpeds.2012.11.081. Epub 2013 Jan 17.

PMID:
23333131
13.

Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Macaubas C, Nguyen K, Deshpande C, Phillips C, Peck A, Lee T, Park JL, Sandborg C, Mellins ED.

Clin Immunol. 2010 Feb;134(2):206-16. doi: 10.1016/j.clim.2009.09.010. Epub 2009 Oct 29.

14.

Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Yokota S, Tanaka T, Kishimoto T.

Ther Adv Musculoskelet Dis. 2012 Dec;4(6):387-97. doi: 10.1177/1759720X12455960.

15.

Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.

Kumar S.

Indian J Pediatr. 2016 Apr;83(4):322-7. doi: 10.1007/s12098-016-2060-z. Epub 2016 Feb 26. Review.

PMID:
26916892
16.

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.

Ann Rheum Dis. 2017 Jan;76(1):166-172. doi: 10.1136/annrheumdis-2015-209020. Epub 2016 Jun 13.

PMID:
27296321
17.

Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?

Behrens EM.

Autoimmun Rev. 2008 Feb;7(4):305-8. doi: 10.1016/j.autrev.2007.11.025. Epub 2008 Jan 4. Review.

PMID:
18295734
18.

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ.

Pediatr Rheumatol Online J. 2015 Dec 3;13:55. doi: 10.1186/s12969-015-0055-3. Review.

19.

Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.

Ravelli A, Grom AA, Behrens EM, Cron RQ.

Genes Immun. 2012 Jun;13(4):289-98. doi: 10.1038/gene.2012.3. Epub 2012 Mar 15. Review.

PMID:
22418018
20.

Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Schulert GS, Grom AA.

Annu Rev Med. 2015;66:145-59. doi: 10.1146/annurev-med-061813-012806. Epub 2014 Nov 5. Review.

PMID:
25386930

Supplemental Content

Support Center